P244 Accuracy of Admission Diagnosis of Pneumonia

Price, LC; Anwar, M. S.; Srikanthan, Karthikan; Bercusson, A; Williams, Emlyn; Prior, Edward; Owusu-Ageyi, A; Umpleby, H. C.; Berry, Marissa J.

doi:10.1136/thoraxjnl-2013-204457.396

Cited by 1 publication

(1 citation statement)

References 1 publication

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This difference is partly explained by inaccuracies in the coding of CAP within the UK Hospital Episode Statistics database; various studies indicate that in about 50% of coded pneumonias, there is no evidence of pneumonia on the chest radiograph [31,32]. Some of the difference may also be due to a true reduction in the overall incidence of CAP in recent years compared to the pre-PCV period [16,33].…”

Section: Strengths and Weaknessesmentioning

confidence: 99%

Impact of infant 13-valent pneumococcal conjugate vaccine on serotypes in adult pneumonia

et al. 2015

View full text Add to dashboard Cite

Infant 13-valent pneumococcal conjugate vaccination (PCV13) was introduced to the UK in 2010. Its impact on serotypes implicated in adult non-bacteraemic pneumococcal pneumonia is not known.Beginning in 2008, a 5-year prospective cohort study of adults admitted to hospital with communityacquired pneumonia (CAP) was conducted. Pneumococcal serotype was established using a validated multiplex immunoassay (Bio-Plex; Bio-Rad, Hercules, CA, USA).The overall incidence for hospitalised CAP and pneumococcal CAP was 79.9 (95% CI 76.6-83.3) and 23.4 (95% CI 21.6-25.3) per 100 000 population, respectively. A decline in CAP (incidence rate ratio (IRR) per year 0.96, 95% CI 0.94-0.99; p=0.016) and pneumococcal CAP (IRR per year 0.84, 95% CI 0.80-0.89; p<0.001) was observed over the 5-year period of the study. Between the pre-and post-PCV13 periods of the study, the incidence of CAP due to serotypes included in the PCV7 declined by 88% (IRR 0.12, 95% CI 0.08-0.20; p<0.001), and CAP due to the additional 6 serotypes in PCV13 declined by 30% (IRR 0.70, 95% CI 0.51-0.96; p=0.024).Incidence of adult pneumococcal pneumonia declined over the last 5 years, with serotypes included in PCV13 declining post-PCV13 introduction, indicating early herd protection effects from PCV13 infant vaccination on adult non-bacteraemic disease. These effects may accrue over the coming years with implications for national pneumococcal vaccination policies in adults. @ERSpublications This is the first study to indicate herd protection from infant PCV13 on adult non-bacteraemic pneumococcal pneumonia

show abstract

Section: Strengths and Weaknessesmentioning

confidence: 99%